Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 29 |
| Active Pipeline (Recruiting Now) | 16 (5) |
| Completed vs Stopped Early | 7 / 1 (3.5%) |
| Median Closed Actual Enrollment | 37 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Peter MacCallum Cancer Centre | Melbourne | 27 |
| Royal Adelaide Hospital | Adelaide, South Australia | 4 |
| Royal Brisbane and Women's Hospital | Herston, Queensland | 4 |
Explore interactive annual charts and M&A subsidiary rollups in the Peter MacCallum Cancer Centre, Australia Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.